Markets
Why To Keep Buying Fate Therapeutics Inc. (NASDAQ:FATE) while S&P500 loss -0.18%
Fate Therapeutics Inc. (NASDAQ:FATE) has a beta of 1.66. The stock’s Relative Strength Index (RSI) is 60.25, with weekly volatility at 6.40% and ATR at
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.